When Jeremy Nicholl was diagnosed with incurable prostate cancer last year, the 60-year-old photographer decided to film himself undergoing treatment with early docetaxel and hormone therapy, releasing them online as a series called My Beautiful Cancer. We talk to him about why the filming helped him cope with his symptoms and what the public reaction has been to his starkly honest videos.
The Institute of Cancer Research has discovered a genetic mutation in samples of some men's tumours that could make them particularly susceptible to immunotherapy treatment. The researchers are now committed to running clinical trials to prove if their theory is right.
A five-year early-stage study of high-intensity focused ultrasound resulted in tumour progression being halted in men with intermediate-risk, localised prostate cancer. But more evidence is needed to prove its benefits hold up against existing treatment options and for all men with the disease.
BLOG: Abiraterone should continue to be available on the NHS and opened up to all men with newly diagnosed advanced prostated cancer, argues our policy manager Tim Windle, as the UK’s drug guidelines body is set to rule on the future of the treatment.
An early-stage trial of the immunotherapy drug, pembrolizumab, has proven it to be effective for a small number of men with incurable disease. We take a closer a look at how it works and what we're doing to bring the benefits of immunotherapy to many more men with prostate cancer.
Hormone therapy is a treatment that controls rather than cures prostate cancer that has spread, so we’re often asked what’s next if it stops working so well. Our Specialist Nurse, Patricia, looks at the options.
This week the PSA test is in the media spotlight after results from a large prostate cancer trial were released. So what should men do if they are worried about prostate cancer? Who should have a PSA test? Our Specialist Nurse, Ali Rooke sets out the facts.
Our Specialist Nurses received record numbers of enquiries last week after prostate cancer dominated the headlines. So we've pulled together their answers to the most commonly asked questions, as well as footage of our recent Facebook Live Q&A event, to give everyone the lowdown on the UK's third biggest cancer killer.
BLOG: Angela Culhane, our CEO, discusses in further detail the reasons behind this change in figures announced last week.
For the first time, more men are dying from prostate cancer each year than women are from breast cancer, making the male disease the third biggest cancer killer in the UK. We find out why and urge the public to help us raise the £120 million we need to curb the trend.